CPWM
ABCL icon

Cardinal Point Wealth Management’s AbCellera Biologics ABCL Stock Holding History

Cardinal Point Wealth Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-310,120
Closed -$6.82M – 43
2021
Q2 		$6.82M Buy
+310,120
New +$8.55M 3.08% 11

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Cardinal Point Wealth Management's ABCL Position: Q3 2021 in Review

Cardinal Point Wealth Management sold out of AbCellera Biologics (ABCL) in Q3 2021, closing a stake of 310,120 shares — an estimated $6.82M sold.

Cardinal Point Wealth Management first reported a position in ABCL in Q2 2021 and held it in 1 quarter. The position peaked at $6.82M in Q2 2021. 116 funds tracked by Wall St. Rank hold ABCL as of Q3 2021.

  • Cardinal Point Wealth Management reported no remaining AbCellera Biologics position as of Q3 2021 after selling out during the quarter.
  • Cardinal Point Wealth Management sold 310,120 AbCellera Biologics shares in Q3 2021, an estimated $6.82M.
  • Cardinal Point Wealth Management first reported a position in AbCellera Biologics in Q2 2021 and held it in 1 quarter.
  • Cardinal Point Wealth Management's AbCellera Biologics position peaked at $6.82M in Q2 2021.
  • 116 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2021.

Based on Cardinal Point Wealth Management's 13F filing for Q3 2021, filed 5 Nov 2021.